|
Patient's representative reported "one or more biocell devices caused personal injuries and damages including but not limited to the following: plaintiff was implanted with biocell textured breast implants and has suffered, or will suffer, bia-alcl, painful removal procedures, scarring, disfigurement, diagnostics and explant, reconstruction, hospitalization, additional care, capsular contracture, as well as other treatment, therapy, recovery and expense associated with the removal of the biocell textured breast implants, along with increased risk of alcl, fear due to risk of alcl, and any condition or symptoms associated with alcl or the prevention of that issue, and other past and future economic and non-economic damages such as medical care costs, lost wages, lost wage earning capacity and mental pain and suffering, and other physical and emotional manifestations that are severe and ongoing", "desire to have her implants removed due to the increased risk of bia-alcl" and "been diagnosed with bia-alcl".The baker grade of the capsular contracture is unknown.This record is for the left side.The device was explanted.It is unknown if the device will be returned.Patient was hospitalized.Histopathological markers of cd30+ and alk- have not been provided.
|
|
A review of the device history record has been completed.No deviations or non-conformance's noted.Further investigation summary: the review of the documentation associated to the manufacturing process indicates that all devices involved in this work order were released in accordance with abbvie¿s procedures and were no defects/problems/issues found in the documents or in the personnel training related to the reported event.Additionally, no er/ ncr(s) were identified during the investigation associated with this lot and the complaint.According to the complaint review there is no information if the device will be returned for analysis in the device analysis laboratory.However, the reported event lymphoma-alcl-suspected is classified as medical and it is unable to observe, therefore it is unable to be confirmed.A review of the current risk documents was performed, and the event of lymphoma-alcl-suspected is a known event, for which current process controls and inspections are established to reduce the incidence of this defect.Considering that there is no adverse trend for this type of event, no additional actions are deemed required at this time.The issue with lymphoma-alcl-suspected will continue to be monitored and corrective actions will be taken in the future if deemed appropriate.The events of capsular contracture and lymphoma-alcl-suspected are physiological complications and analysis of the device generally does not assist allergan in determining a probable cause for these events.Further information from the reporter regarding event, product, or patient details has been requested.No additional information is available at this time.The reason for reoperation: capsular contracture baker grade unknown, lymphoma-alcl-suspected patient legal representative contact: (b)(6).
|